rituximab,epcoritamab
genmab,abbvie,janssen,roche,biogen
['dlbcl', 'epcore nhl-2', 'epcore,nhl,2', 'nhl', 'epcore,nhl,3', 'epcoritamab']
congress | of presents data from the phase i/ii epcore nhl-2 trial of epcoritamab + rchop in patients with high-risk #dlbcl. n=33
orr=100%
cmr=77% therapy has a manageable safety profile; no new safety signals were detected. #asco22 
A global education platform providing clinical updates on a range of lymphoma subtypes and chronic lymphocytic leukemia (#CLL) #lymsm